Attorney's Docket No.!

JUL 9 2 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : P. Kazemi-Esfarjani et al.

Art Unit: 1636

Serial No.: 09/639,207

Examiner : S. Pappu

Filed

August 14, 2000

Title :

AN ANIMAL MODEL OF POLYGLUTAMINE TOXICITY, METHODS

OF USE, AND MODULATORS OF POLYGLUTAMINE TOXICITY

U.S. Patent and Trademark Office Arlington, VA 22202

## RESPONSE

In response to the action mailed February 28, 2002, the time for responding having been extended to June 28, 2002, by the accompanying fee and petition under 1.136, please amend the application as follows:

## In the specification:

The paragraph beginning at page 1, line 20, and bridging to page 2, line 2, has been amended as follows:

--Expansion of polyCAG tracts is associated with human hereditary neurodegenerative disorders and neuronal toxicity (Kaytor et al., J. Biol. Chem., 274:37507-37510 (1999)). Huntington's disease and several other hereditary neurodegenerative disorders are characterized by expansion of a polyglutamine sequence (LaSpada et al., Nature, 352:77-79 (1991); Koide et al., Nat. Genet., 6:9-13 (1994); Kawaguchi et al., Nat. Genet., 8:221-228 (1994); Orr et al., Nat. Genet., 4:221-226 (1993); Sanpei et al., Nat. Genet., 14:277-284 (1996); and Zhuchenko et al., Nat. Genet., 15:62-69 (1997)). The expanded polyCAG tracts encode abnormally long polyglutamine sequences within specific proteins promoting their nuclear and/or cytoplasmic

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

22202.

Date of Deposit

Signatur

Typed or Printed Name of Person Signing Certificate

07/09/2002 ADSMAN1 00000029 09639207

01 FC:215

55.00 OP

-